Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator ...

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Craig Morgan outlines why comparator clinical trials are useful and provides points to consider to ensure the best outcome. In clinical trials, a comparator drug (defined as ‘an investigational or ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Topline data were announced from two phase 3 studies evaluating setrusumab in patients with osteogenesis imperfecta.

Chile has selected China's vaccine company, Sinovac Biotech, as the exclusive supplier of its influenza vaccines for 2026 — ...

The positive interim results of the Phase 1a SAD/MAD trial support rapid advancement of clinical development. Aclaris expects to initiate a Phase 1b POC trial in AD imminently and a Phase 1b POC trial ...

ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...

Ultragenyx Pharmaceutical and Mereo BioPharma Group saw their shares plummet after ringing out 2025 by announcing the failures of their brittle bone disease candidate setrusumab (UX143) in a pair of ...